Decitabine co-operates with the IL-33/ST2 axis modifying the tumor microenvironment and improving the response to PD-1 blockade in melanoma
Our findings indicate that DAC effectively co-operates with IL-33/ST2 axis against melanoma through immune cell recruitment and epigenetic regulation of gene expression, thus remodeling the tumor immune microenvironment to overcome resistance to PD- 1 inhibition.
Authors
- Massimo Spada
- Adriana Rosa Gambardella (ORCID: https://orcid.org/0000-0002-5335-8650)
- Carlo Curcio
- Fabrizio Mattei (ORCID: https://orcid.org/0000-0002-5357-7773)
- Sara Andreone (ORCID: https://orcid.org/0000-0001-7265-0465)
- Giovanna Schiavoni (ORCID: https://orcid.org/0000-0001-9135-0556)
- Anna Maria Pacca
- Carla Buccione
- Luca Businaro (ORCID: https://orcid.org/0000-0002-5251-093X)
- Jacopo Mancini (ORCID: https://orcid.org/0000-0002-8981-3088)
- Adele De Ninno (ORCID: https://orcid.org/0000-0003-3139-2820)
- Claudia Afferni (ORCID: https://orcid.org/0000-0002-8567-7365)
- Maria Teresa D’Urso
- F. Noto (ORCID: https://orcid.org/0009-0000-6359-8060)
- Daniele Macchia
Institutions
- Istituto Superiore di Sanità (IT)
- Center for Biomolecular Nanotechnologies (IT)
Publication Details
- Journal
- Journal of Experimental & Clinical Cancer Research
- Published
- 2025-05-02
- DOI
- https://doi.org/10.1186/s13046-025-03381-z
- Citations
- 3
- Primary Topic
- IL-33, ST2, and ILC Pathways
- Type
- article
- Field-Weighted Citation Impact
- 2.39
Funders
- European Commission
- Associazione Italiana per la Ricerca sul Cancro